BIOMAT Database Logo BIOMAT Database Logo

Synthesis of [1,2,4]triazolo[4,3-a]quinoxaline-1,3,4-oxadiazole derivatives as potent antiproliferative agents via a hybrid pharmacophore approach. 2020

Daiki Kaneko, and Masayuki Ninomiya, and Rina Yoshikawa, and Yukari Ono, and Amol D Sonawane, and Kaori Tanaka, and Atsuyoshi Nishina, and Mamoru Koketsu
Department of Chemistry and Biomolecular Science, Faculty of Engineering, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan.

Imiquimod (1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine) is efficacious in topical therapy for certain types of skin cancers. Structurally similar EAPB0203 (N-methyl-1-(2-phenethyl)imidazo[1,2-a]quinoxalin-4-amine) has been shown higher in vitro potency than imiquimod. Besides, triazole, oxadiazole, and thiadiazole rings are privileged building blocks in drug design. A series of [1,2,4]triazolo[4,3-a]quinoxaline-1,3,4-oxadiazole and [1,2,4]triazolo[4,3-a]quinoxaline-1,3,4-thiadiazole derivatives were therefore synthesized by incorporation of these rings into the structure of EAPB0203 and assessed their antiproliferative effects against various cancer cell lines. The 1,3,4-oxadiazole derivatives demonstrated the superior effectiveness compared to imiquimod and EAPB0203. Our findings highlight the excellent potential of [1,2,4]triazolo[4,3-a]quinoxaline-1,3,4-oxadiazole derivatives as anticancer agents.

UI MeSH Term Description Entries
D010069 Oxadiazoles Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms. Oxadiazole
D011810 Quinoxalines Quinoxaline
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured

Related Publications

Daiki Kaneko, and Masayuki Ninomiya, and Rina Yoshikawa, and Yukari Ono, and Amol D Sonawane, and Kaori Tanaka, and Atsuyoshi Nishina, and Mamoru Koketsu
Synthesis and Biological Evaluation of Some [1,2,4]Triazolo[4,3-a]quinoxaline Derivatives as Novel Anticonvulsant Agents.
January 2013, ISRN organic chemistry,
Daiki Kaneko, and Masayuki Ninomiya, and Rina Yoshikawa, and Yukari Ono, and Amol D Sonawane, and Kaori Tanaka, and Atsuyoshi Nishina, and Mamoru Koketsu
1,2,4-Triazolo[4,3-a]quinoxaline-1,4-diones as antiallergic agents.
March 1985, Journal of medicinal chemistry,
Daiki Kaneko, and Masayuki Ninomiya, and Rina Yoshikawa, and Yukari Ono, and Amol D Sonawane, and Kaori Tanaka, and Atsuyoshi Nishina, and Mamoru Koketsu
Efficient synthesis and evaluation of novel 6-arylamino-[1,2,4]triazolo[4,3-a]pyridine derivatives as antiproliferative agents.
November 2022, Bioorganic & medicinal chemistry letters,
Daiki Kaneko, and Masayuki Ninomiya, and Rina Yoshikawa, and Yukari Ono, and Amol D Sonawane, and Kaori Tanaka, and Atsuyoshi Nishina, and Mamoru Koketsu
Synthesis of some new 4-styryltetrazolo[1,5-a]quinoxaline and 1-substituted-4-styryl[1,2,4]triazolo[4,3-a]quinoxaline derivatives as potent anticonvulsants.
March 2009, European journal of medicinal chemistry,
Daiki Kaneko, and Masayuki Ninomiya, and Rina Yoshikawa, and Yukari Ono, and Amol D Sonawane, and Kaori Tanaka, and Atsuyoshi Nishina, and Mamoru Koketsu
Synthesis and Screening of New [1,3,4]Oxadiazole, [1,2,4]Triazole, and [1,2,4]Triazolo[4,3-b][1,2,4]triazole Derivatives as Potential Antitumor Agents on the Colon Carcinoma Cell Line (HCT-116).
January 2021, ACS omega,
Daiki Kaneko, and Masayuki Ninomiya, and Rina Yoshikawa, and Yukari Ono, and Amol D Sonawane, and Kaori Tanaka, and Atsuyoshi Nishina, and Mamoru Koketsu
Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
August 2022, Molecular diversity,
Daiki Kaneko, and Masayuki Ninomiya, and Rina Yoshikawa, and Yukari Ono, and Amol D Sonawane, and Kaori Tanaka, and Atsuyoshi Nishina, and Mamoru Koketsu
Novel [1,2,4]triazolo[1,5-a]pyrimidine derivatives as potent antitubulin agents: Design, multicomponent synthesis and antiproliferative activities.
November 2019, Bioorganic chemistry,
Daiki Kaneko, and Masayuki Ninomiya, and Rina Yoshikawa, and Yukari Ono, and Amol D Sonawane, and Kaori Tanaka, and Atsuyoshi Nishina, and Mamoru Koketsu
New 1,3,4-oxadiazole-chalcone/benzimidazole hybrids as potent antiproliferative agents.
February 2023, Archiv der Pharmazie,
Daiki Kaneko, and Masayuki Ninomiya, and Rina Yoshikawa, and Yukari Ono, and Amol D Sonawane, and Kaori Tanaka, and Atsuyoshi Nishina, and Mamoru Koketsu
Quinoxaline derivatives. Part II: Synthesis and antimicrobial testing of 1,2,4-triazolo[4,3-a]quinoxalines, 1,2,4-triazino[4,3-a]quinoxalines and 2-pyrazolylquinoxalines.
November 1999, Die Pharmazie,
Daiki Kaneko, and Masayuki Ninomiya, and Rina Yoshikawa, and Yukari Ono, and Amol D Sonawane, and Kaori Tanaka, and Atsuyoshi Nishina, and Mamoru Koketsu
Design, synthesis, and molecular docking studies of new [1,2,4]triazolo[4,3-a]quinoxaline derivatives as potential A2B receptor antagonists.
February 2021, Molecular diversity,
Copied contents to your clipboard!